Drugs / Tislelizumab Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05516914 | Sep 2022 → Jan 2026 | cancer | Nanjing Leads Biolabs Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tislelizumab Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05516914 ↗ |
| Route | Intravenous | “Initial dose; Q3W; intravenous infusion” NCT05516914 ↗ |